Communications Biology (Nov 2023)

Biologically derived epicardial patch induces macrophage mediated pathophysiologic repair in chronically infarcted swine hearts

  • J. J. Lancaster,
  • A. Grijalva,
  • J. Fink,
  • J. Ref,
  • S. Daugherty,
  • S. Whitman,
  • K. Fox,
  • G. Gorman,
  • L. D. Lancaster,
  • R. Avery,
  • T. Acharya,
  • A. McArthur,
  • J. Strom,
  • M. K. Pierce,
  • T. Moukabary,
  • M. Borgstrom,
  • D. Benson,
  • M. Mangiola,
  • A. C. Pandey,
  • M. R. Zile,
  • A. Bradshaw,
  • J. W. Koevary,
  • S. Goldman

DOI
https://doi.org/10.1038/s42003-023-05564-w
Journal volume & issue
Vol. 6, no. 1
pp. 1 – 14

Abstract

Read online

Abstract There are nearly 65 million people with chronic heart failure (CHF) globally, with no treatment directed at the pathologic cause of the disease, the loss of functioning cardiomyocytes. We have an allogeneic cardiac patch comprised of cardiomyocytes and human fibroblasts on a bioresorbable matrix. This patch increases blood flow to the damaged heart and improves left ventricular (LV) function in an immune competent rat model of ischemic CHF. After 6 months of treatment in an immune competent Yucatan mini swine ischemic CHF model, this patch restores LV contractility without constrictive physiology, partially reversing maladaptive LV and right ventricular remodeling, increases exercise tolerance, without inducing any cardiac arrhythmias or a change in myocardial oxygen consumption. Digital spatial profiling in mice with patch placement 3 weeks after a myocardial infarction shows that the patch induces a CD45pos immune cell response that results in an infiltration of dendritic cells and macrophages with high expression of macrophages polarization to the anti-inflammatory reparative M2 phenotype. Leveraging the host native immune system allows for the potential use of immunomodulatory therapies for treatment of chronic inflammatory diseases not limited to ischemic CHF.